5 October 2017 - Globally recognised technology that could spare thousands of Australian breast cancer patients from unnecessary chemotherapy will remain out of reach for many after the federal government ­refused to fund the expensive test.

The test, which provides a prognosis for early-stage breast cancer patients on the likelihood the cancer will recur, is reimbursed in the US, Canada, Britain and throughout Europe.

Specialised Therapeutics Australia has distributed the test here since 2014 at an out-of-pocket cost to patients of $4500, which it said was the lowest price available in the world.

Read The Australian article